il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells
Recurrent Malignant Glioma
City of Hope Medical CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Recurrent Malignant Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE Oblato, Inc. | Phase 2 | B |
WP 1066 M.D. Anderson Cancer Center | Phase 1 | CC |
Arm 2: Il13Ra2-Specific Car Tcm Cells City of Hope Medical Center | Phase 1 | CC |
c134 University of Alabama at Birmingham | Phase 1 | CC |
View all 12 →
Same molecule, other indications
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →